Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

Hanall Biopharma, Approved for Clinical Trial Phase 1 of “HL036,” New Medicine for Dry Eye Disease
Hanall Biopharma, Approved for Clinical Trial Phase 1 of “HL036,” New Medicine for Dry Eye Disease

Advanced Anti-TNF Antibody… Eye Drop Bio Better as Eyewash

Outstanding Preclinical Result: High Stability and Effect… Clinical Trial Phase 1 to be Completed by the Second Quarter of the Next year


On 19th, Hanall Biopharma (CEO Park Seung-guk and CEO Yun Jae-chun) has announced that the company has received the approval for the clinical trial phase 1 on “HL036,” the new medicine for dry eye disease, by the Ministry of Food and Drug Safety.

Dry eye disease is a disease from damaged surface of eyeball by excessive evaporation of tear or insufficient formation of tear, and the disease occurs from high osmosis and accumulation of infective material within tear. From aging society, excessive use of computer, and environmental change due to use of air conditioning and heating equipment, the number of dry eye disease patients are increasing.

A new medicine under development by Hanall Biopharma for dry eye disease, “HL036” is Bio Better medicine of eye drop for eye wash made of advanced anti-TNF antibody. 


Bio Better is a field to enhance medicinal effect and convenience of conventional original bio medicines through advanced technology, and it takes 47.7% of the protein bio medicine market over the world (20 trillion KRW).

Especially, the anti-TNF antibody is the largest antibody medicine with the market size of 26 trillion KRW over the world, and the representative product is Enbrel Inj for treatment of rheumatoid arthritis. It restricts combination with TNF receptor, which brings various inflammatory disease, to have outstanding therapeutic mechanism for anti-inflammation.


HL036” is Bio Better with molecular reorganization that has been improved to indicate more stability and vitality and high tissue-distribution rate compare to conventional anti-TNF antibody. The advanced Bio Better technology of Hanall called “Resistein” Technologyhas been used, and by using such technology, it may be applied to arthritis, chronic respiratory infection, neurological infection, inflammatory bowel disease, and other severe inflammation besides a dry eye disease.


One of the staffs of Hanall Biopharma has said, “As a result of pre-clinical trial (animal test), the effect and stability of “HL036” are high, and the clinical trial phase1 to be performed at the Seoul National University Hospital will be completed by the second quarter of the next year.”